Second malignancies in Philadelphia-positive and -negative  myeloproliferative neoplasms: A single center study

Soner Solmaz; Aslı Korur; Çiğdem GEREKLİOĞLU; Süheyl ASMA; Nurhilal BÜYÜKKURT; Mutlu KASAR; Mahmut YERAL; İlknur KOZANOĞLU; Can Boğa; Hakan ÖZDOĞU

doi:10.5578/gmj.32154

Authors

Soner Solmaz Clinic of Hematology, Başkent University Adana Hospital, Adana
Aslı Korur Clinic of Family Medicine, Başkent University Adana Hospital, Adana
Çiğdem GEREKLİOĞLU Clinic of Family Medicine, Başkent University Adana Hospital, Adana
Süheyl ASMA Clinic of Family Medicine, Başkent University Adana Hospital, Adana
Nurhilal BÜYÜKKURT Clinic of Hematology, Başkent University Adana Hospital, Adana
Mutlu KASAR Clinic of Hematology, Başkent University Adana Hospital, Adana
Mahmut YERAL Clinic of Hematology, Başkent University Adana Hospital, Adana
İlknur KOZANOĞLU Clinic of Hematology Research Laboratory, Başkent University Adana Hospital, Adana
Can Boğa Clinic of Hematology, Başkent University Adana Hospital, Adana
Hakan ÖZDOĞU Clinic of Hematology, Başkent University Adana Hospital, Adana

DOI:

https://doi.org/10.5578/gmj.32154

Keywords:

Myeloproliferative neoplasms, chronic myeloid leukemia, second malignancy

Abstract

Introduction: Leukemic transformation (LT) of both Philadelphia (Ph) -positive and -negative myeloprolifetarive neoplasms (MPNs) is a well-known subject. However sufficient data are not available in literature from Turkey about the frequency of second malignancies (SMs) except LT in patients with MPNs. In this study, it was aimed to investigate the frequency of SMs in Ph-positive or -negative MPN cases.
Materials and Methods: A total of 438 patients diagnosed with classical MPN according to WHO 2008 diagnostic criteria were included in the study.
Results: SMs were detected in 15 out of 438 patients (3.4%). In this study, cancer incidence rate was found higher (1149.8/100.000 person-years for males and 540.8/100.000 person-years for females with MPNs) compared with Turkey data.
Conclusion: SM frequency is significantly higher than normal population in patients with MPNs. Therefore these patients should be carefully examined for SM symptoms and signs.

Metrics

Metrics Loading ...

References

Klco JM, Vij R, Kreisel FH, Hassan A, Frater JL. Molecular pathology of myeloproliferative neoplasms. Am J Clin Pathol 2010;133:602-15.

Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-38.

Available from: http://globocan.iarc.fr/Default.aspx

Rebora P, Czene K, Antolini L, Gambacorti Passerini C, Reilly M, Valsecchi MG. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study.Am J Epidemiol 2010;172:1028-33.

Voglova J, Muzik J, Faber E, Zackova D, Klamova H, Steinerova K, et al. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma 2011;58:256-62.

Shah BK, Ghimire KB. Second primary malignancies in chronic myeloid leukemia. Indian J Hematol Blood Transfus 2014;30:236-40.

Budrukkar A, Muttagi S, Shahid T, Chatturvedi P, Banavali S, Laskar SG, et al. Second primary head and neck squamous cell cancers with aggressive behavior in patients with chronic myeloid leukaemia. Br J Oral Maxillofac Surg 2012;50:504-7.

Slade R, Thomas WE. Gastrointestinal malignancies as a complication of chronic myeloid leukaemia. Br J Clin Pract 1990;44:76-8.

Frustaci A, Breccia M, Cannella L, Stefanizzi C, Alimena G. Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: report of two cases and review of the literature. Leuk Res 2009;33:200-1.

Tillawi IS. Synchronous occurrence of Philadelphia chromosomepositive chronic myelogenous leukemia and breast cancer. Saudi Med J 2007;28:291-4.

Kim HJ, Kim MJ, Lee MJ, Ahn JH, Kim HS, Kim IS, et al. Coexistence of chronic myeloid leukemia and pulmonary plasmacytoma mimicking primary lung cancer. Int J Hematol 2010;92:651-4.

D’Arena G, Gemei M, Luciano L, D’Auria F, Deaglio S, Statuto T, et al. Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic eventsand a common treatment? J Clin Oncol 2012;30:e327-30.

Radaelli F, Onida F, Rossi FG, Zilioli VR, Colombi M, Usardi P, et al. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution. Hematology 2008;13:195-202.

Kissova J, Ovesna P, Penka M, Bulikova A, Kiss I. Second malignancies in philadelphia-negative myeloproliferative neoplasms-singlecenter experience. Anticancer Res 2014;34:2489-96.

Zielinska P, Markiewicz M, Dzierzak-Mietla M, Koclega A, Helbig G, Kyrcz-Krzemien S. Coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasm. Case Rep Oncol Med 2014;2014:512928. doi: 10.1155/2014/512928.

Trifa AP, Cucuianu A, Popp RA, Paţiu M, Selicean C, Militaru MS, et al. Concomitant myeloproliferative and lymphoid neoplasms in two patients positive for JAK2 V617F mutation. Case Report and Literature Review. Indian J Hematol Blood Transfus 2014;30:120-3.

Papageorgiou MV, Alexopoulou A, Kontopidou F, Filiotou A, Koskinas J, Pectasides D. Concomitant diagnosis of myeloproliferative neoplasm and non-Hodgkin’s lymphoma in a patient with portal vein thrombosis. Anticancer Res 2011;31:1467-9.

Malhotra J, Kremyanskaya M, Schorr E, Hoffman R, Mascarenhas J. Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia. Clin Lymphoma Myeloma Leuk 2014;14:31-6.

Stein BL. Chronic myeloid leukemia and risk of second malignancy in two eras of treatment. Leuk Lymphoma 2012;53:1651-3.